Biopharma, medtech faced tight funding in Q1

When it comes to the life sciences industry, biopharma and medtech continue to power through market challenges.

Biopharma R&D partnerships ticked up slightly in the first three months of 2023, while venture continued its yearlong decline. In medtech, R&D partnerships and venture held steady in Q1, down from record highs during the pandemic.

J.P. Morgan’s biopharma therapeutics and medtech licensing reports examine activity in each sector to provide insights on industry trends we might see for the remainder of 2023. The reports, powered by DealForma, highlight:

• Deal values in biopharma licensing partnerships
• Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
• Venture investment amounts in therapeutic and platform companies
• The advanced therapies that are seeing healthy investment and dealmaking
• IPO and M&A activity in each sector

Download the full reports to understand these life sciences dealmaking trends and see what they may mean for the months ahead.